1. Vandamme AM, De Clercq E: Antiviral Therapy. Volume chap 12. ASM Press, Washington, US; 2001:243–277.
2. Rambaut A, Posada D, Crandall KA, Holmes EC: The causes and consequences of HIV evolution. Nat Rev Genet 2004, 5: 52–61. 10.1038/nrg1246
3. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, BrunVezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr H, Faudon J, Gatti G, Gerstoft J, Hall W, Hatzakis A, Hellmann N, Horban A, Lundgren J, Kempf D, Miller M, Miller V, Myers T, Nielsen C, Opravil M, Palmisano L, Perno C, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit J, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L: Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004, 9(6):829–48.
4. Wainberg MA, Brenner BG, Turner D: Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2005, 49(5):1671–1678. 10.1128/AAC.49.5.1671-1678.2005
5. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD: Drug Susceptibility in HIV Infection After Viral Rebound in Patients Receiving Indinavir-Containing Regimens. JAMA 2000, 283(2):229–234. 10.1001/jama.283.2.229